Number of patients experiencing adverse events classified as related to treatment with SGN-30, by dose level
| Adverse event . | Dose . | ||||
|---|---|---|---|---|---|
| 2 mg/kg, n = 6 . | 4 mg/kg, n = 6 . | 8 mg/kg, n = 6 . | 12 mg/kg, n = 6 . | Total (%), n = 24 . | |
| Nausea | 2 | 0 | 1 | 0 | 3 (13) |
| Fatigue | 1 | 1 | 0 | 1 | 3 (13) |
| Pyrexia | 2 | 0 | 1 | 0 | 3 (13) |
| Anorexia | 1 | 0 | 1 | 0 | 2 (8) |
| Myalgia | 1 | 0 | 1 | 0 | 2 (8) |
| Headache | 1 | 1 | 0 | 0 | 2 (8) |
| Pruritis | 0 | 1 | 0 | 1 | 2 (8) |
| Anemia | 0 | 0 | 1 | 0 | 1 (4) |
| Diarrhea | 1 | 0 | 0 | 0 | 1 (4) |
| Fecal abnormality | 1 | 0 | 0 | 0 | 1 (4) |
| Oral pain | 0 | 0 | 0 | 1 | 1 (4) |
| Infusion site warmth | 0 | 0 | 1 | 0 | 1 (4) |
| Hepatic pain | 0 | 1 | 0 | 0 | 1 (4) |
| Herpes zoster | 0 | 0 | 0 | 1 | 1 (4) |
| Dizziness | 1 | 0 | 0 | 0 | 1 (4) |
| Dysgeusia | 0 | 1 | 0 | 0 | 1 (4) |
| Pharyngitis | 1 | 0 | 0 | 0 | 1 (4) |
| Rash | 1 | 0 | 0 | 0 | 1 (4) |
| Sweating | 0 | 0 | 1 | 0 | 1 (4) |
| Hot flushes | 0 | 0 | 0 | 1 | 1 (4) |
| Adverse event . | Dose . | ||||
|---|---|---|---|---|---|
| 2 mg/kg, n = 6 . | 4 mg/kg, n = 6 . | 8 mg/kg, n = 6 . | 12 mg/kg, n = 6 . | Total (%), n = 24 . | |
| Nausea | 2 | 0 | 1 | 0 | 3 (13) |
| Fatigue | 1 | 1 | 0 | 1 | 3 (13) |
| Pyrexia | 2 | 0 | 1 | 0 | 3 (13) |
| Anorexia | 1 | 0 | 1 | 0 | 2 (8) |
| Myalgia | 1 | 0 | 1 | 0 | 2 (8) |
| Headache | 1 | 1 | 0 | 0 | 2 (8) |
| Pruritis | 0 | 1 | 0 | 1 | 2 (8) |
| Anemia | 0 | 0 | 1 | 0 | 1 (4) |
| Diarrhea | 1 | 0 | 0 | 0 | 1 (4) |
| Fecal abnormality | 1 | 0 | 0 | 0 | 1 (4) |
| Oral pain | 0 | 0 | 0 | 1 | 1 (4) |
| Infusion site warmth | 0 | 0 | 1 | 0 | 1 (4) |
| Hepatic pain | 0 | 1 | 0 | 0 | 1 (4) |
| Herpes zoster | 0 | 0 | 0 | 1 | 1 (4) |
| Dizziness | 1 | 0 | 0 | 0 | 1 (4) |
| Dysgeusia | 0 | 1 | 0 | 0 | 1 (4) |
| Pharyngitis | 1 | 0 | 0 | 0 | 1 (4) |
| Rash | 1 | 0 | 0 | 0 | 1 (4) |
| Sweating | 0 | 0 | 1 | 0 | 1 (4) |
| Hot flushes | 0 | 0 | 0 | 1 | 1 (4) |